181 related articles for article (PubMed ID: 27932529)
1. Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis.
Tritos NA; Chanson P; Jimenez C; King D; Jönsson PJ; Klibanski A; Biller BM
Eur J Endocrinol; 2017 Feb; 176(2):213-220. PubMed ID: 27932529
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.
Freda PU; Gordon MB; Kelepouris N; Jonsson P; Koltowska-Haggstrom M; van der Lely AJ
Endocr Pract; 2015 Mar; 21(3):264-74. PubMed ID: 25370326
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.
Trainer PJ; Ezzat S; D'Souza GA; Layton G; Strasburger CJ
Clin Endocrinol (Oxf); 2009 Oct; 71(4):549-57. PubMed ID: 19438906
[TBL] [Abstract][Full Text] [Related]
4. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
Ezzat S; Gaspo R; Serri O; Ur E; Chik CL
Clin Invest Med; 2009 Dec; 32(6):E265. PubMed ID: 20003832
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
van der Lely AJ; Biller BM; Brue T; Buchfelder M; Ghigo E; Gomez R; Hey-Hadavi J; Lundgren F; Rajicic N; Strasburger CJ; Webb SM; Koltowska-Häggström M
J Clin Endocrinol Metab; 2012 May; 97(5):1589-97. PubMed ID: 22362824
[TBL] [Abstract][Full Text] [Related]
6. Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY.
Chanson P; Brue T; Delemer B; Caron P; Borson-Chazot F; Zouater H;
Ann Endocrinol (Paris); 2015 Dec; 76(6):664-70. PubMed ID: 26596374
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy.
Ghigo E; Biller BM; Colao A; Kourides IA; Rajicic N; Hutson RK; De Marinis L; Klibanski A
J Endocrinol Invest; 2009 Dec; 32(11):924-33. PubMed ID: 20009494
[TBL] [Abstract][Full Text] [Related]
8. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
[TBL] [Abstract][Full Text] [Related]
9. All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis.
Tritos NA; Mattsson AF; Vila G; Biller BMK; Klibanski A; Valluri S; Hey-Hadavi J; Kelepouris N; Jimenez C
Eur J Endocrinol; 2020 Mar; 182(3):285-292. PubMed ID: 31917681
[TBL] [Abstract][Full Text] [Related]
10. The German ACROSTUDY: past and present.
Buchfelder M; Schlaffer S; Droste M; Mann K; Saller B; Brübach K; Stalla GK; Strasburger CJ;
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S3-S10. PubMed ID: 19684061
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Yamaguchi H; Shimatsu A; Okayama A; Sato T
Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
[TBL] [Abstract][Full Text] [Related]
12. Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort.
Sievers C; Baur DM; Schwanke A; Buchfelder M; Droste M; Mann K; Stalla GK
Pituitary; 2015 Dec; 18(6):916-23. PubMed ID: 26224528
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly.
Shimatsu A; Nagashima M; Hashigaki S; Ohki N; Chihara K
Endocr J; 2016 Apr; 63(4):337-47. PubMed ID: 26796763
[TBL] [Abstract][Full Text] [Related]
15. ACROSTUDY: Status Update on 469 Patients.
Brue T
Horm Res; 2009 Jan; 71 Suppl 1():34-8. PubMed ID: 19153503
[TBL] [Abstract][Full Text] [Related]
16. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
17. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
[TBL] [Abstract][Full Text] [Related]
18. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
Parkinson C; Whatmore AJ; Yates AP; Drake WM; Brabant G; Clayton PE; Trainer PJ
Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793
[TBL] [Abstract][Full Text] [Related]
19. Lessons from 6 years of GH receptor antagonist therapy for acromegaly.
Trainer PJ
J Endocrinol Invest; 2003; 26(10 Suppl):44-52. PubMed ID: 15497659
[TBL] [Abstract][Full Text] [Related]
20. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ
Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
